Laboratory of Drug Design and Medicinal Chemistry

Laboratory of, Japan

Laboratory of Drug Design and Medicinal Chemistry

Laboratory of, Japan
SEARCH FILTERS
Time filter
Source Type

Itoh T.,Laboratory of Drug Design and Medicinal Chemistry | Yoshimoto N.,Showa Pharmaceutical University | Yamamoto K.,Laboratory of Drug Design and Medicinal Chemistry | Yamamoto K.,Showa Pharmaceutical University
Heterocycles | Year: 2010

To study structure-activity relationships of oxidized fatty acids for the activation of peroxisome proliferator-activated receptors (PPARs), which are ligand-dependent transcription factors, we synthesized a series of oxidized fatty acids via iodolactone as a key intermediate. © 2010 The Japan Institute of Heterocyclic Chemistry.


Yoshimoto N.,Laboratory of Drug Design and Medicinal Chemistry | Yoshimoto N.,Showa Pharmaceutical University | Sakamaki Y.,Laboratory of Drug Design and Medicinal Chemistry | Sakamaki Y.,Tokyo Medical and Dental University | And 8 more authors.
Journal of Medicinal Chemistry | Year: 2012

Previously, we reported that 22S-butyl-25,26,27-trinor-1α24- dihydroxyvitamin D 32 represents a new class of antagonist for the vitamin D receptor (VDR). The crystal structure of the ligand-binding domain (LBD) of VDR complexed with 2 showed the formation of a butyl pocket to accommodate the 22-butyl group and insufficient interactions between ligand 2 and the C-terminus of VDR. Here, we designed and synthesized new analogues 5a-c and evaluated their biological activities to probe whether agonistic activity is recovered when the analogue restores interactions with the C-terminus of VDR. Analogues 5a-c exhibited full agonistic activity in transactivation. Interestingly, 5c, which bears a 24-diethyl group, completely recovered agonistic activity, although 3c and 4c act as an antagonist and a weak agonist, respectively. The crystal structures of VDR-LBD complexed with 3a, 4a, 5a, and 5c were solved, and the results confirmed that butyl pocket formation in VDR strongly affects the agonistic or antagonistic behaviors of ligands. © 2012 American Chemical Society.

Loading Laboratory of Drug Design and Medicinal Chemistry collaborators
Loading Laboratory of Drug Design and Medicinal Chemistry collaborators